drugset
Drugs / Olamkicept
last change Nov 2024 re-read 3 minutes ago

Olamkicept

also known as FE 999301 · TJ301

targets IL6 via inhibition

Developed for
ulcerative colitis
Investigated by
Ferring Pharmaceuticals · I-Mab Biopharma HongKong Limited

Trials 2

today NCT06298032 · Ph 1 NCT03235752 · Ph 2
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06298032 Feb → Nov 2024 inflammatory bowel disease Ferring Pharmaceuticals Completed No outcome recorded
Phase 21 trial
Phase 2 NCT03235752 Feb 2018 → Dec 2020 ulcerative colitis I-Mab Biopharma HongKong Limited Completed Mixed
Comparator or background therapy1 trial
Phase 1 NCT06515834 Comparator Jul → Nov 2024 — Ferring Pharmaceuticals Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2022-06-09 Ferring Pharmaceuticals Ferring Announces New Collaboration for Development of Olamkicept ferring.com ↗

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Olamkicept “Olamkicept (FE 999301) has been shown in vitro to be a selective IL-6 trans-signalling inhibitor and administered at lower doses, it has proven to induce clinical improvement...” NCT06515834 ↗
1

NCT06298032 ↗
Known as FE 999301 “Olamkicept (FE 999301) has been shown in vitro to be a selective IL-6 trans-signalling inhibitor and administered at lower doses, it has proven to induce clinical improvement...” NCT06515834 ↗
Known as TJ301 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03235752 ↗
Action Inhibit “selectively inhibits interleukin 6 (IL-6) trans-signaling” PMID 36881032 ↗ Mar 2023
Modality Protein / enzyme biologic “Olamkicept, a soluble gp130-Fc-fusion-protein” PMID 36881032 ↗ Mar 2023
Route Intravenous “biweekly intravenous infusion of olamkicept 600 mg” PMID 36881032 ↗ Mar 2023
Target IL6 “selectively inhibits interleukin 6 (IL-6) trans-signaling by binding the soluble IL-6 receptor/IL-6 complex” PMID 36881032 ↗ Mar 2023